Androgen pathway resistance in prostate cancer and therapeutic implications

Keyphrases

• Prostate Cancer 100%
• Androgen Signaling 100%
• Androgens 100%
• Castration-resistant 100%
• Resistance Mechanisms 100%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 100%
• Androgen Therapy 100%
• Therapeutic Implications 100%
• Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 50%
• Clinical Trials 50%
• Androgen Receptor 50%
• Clinical Data 50%
• Castration-resistant Prostate Cancer 50%
• Literature Search 50%
• Chemotherapy 50%
• Therapeutic Strategies 50%
• Enzalutamide 50%
• Treatment Decisions 50%
• Abiraterone 50%
• Therapy Resistance 50%
• Optimal Treatment 50%
• Drug Resistance Mechanisms 50%
• Resistance Pathways 50%
• Expert Opinion 50%
• Resistant Disease 50%
• Specific Biomarkers 50%
• Hormonal Therapy 50%
• Radiopharmaceuticals 50%
• Hormonal Agents 50%
• Incurable Disease 50%
• Area Cover 50%
• Novel Hormonal Therapy 50%
• Therapy Mechanism 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Androgen 100%
• Castration Resistant Prostate Cancer 75%
• Diseases 75%
• Hormone Cancer Therapy 50%
• Androgen Receptor 50%
• Clinical Trial 25%
• Chemotherapy 25%
• Enzalutamide 25%
• Biological Marker 25%
• Abiraterone 25%
• Therapy Resistance 25%
• Immunotherapy 25%
• Drug Resistance 25%